D L Bemis

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. ncbi Dietary agents/supplements hit the clinic for prostate cancer chemoprevention
    Debra L Bemis
    Department of Urology, Columbia University Medical Center, New York, NY 10032, USA
    Discov Med 7:33-8. 2007
  2. ncbi Anti-prostate cancer activity of a beta-carboline alkaloid enriched extract from Rauwolfia vomitoria
    D L Bemis
    Department of Urology, College of Physicians and Surgeons, Columbia University Medical Center, Herbert Irving Pavilion, New York, NY 10032, USA
    Int J Oncol 29:1065-73. 2006
  3. ncbi Clinical trials of natural products as chemopreventive agents for prostate cancer
    Debra L Bemis
    Columbia University Medical Center, Department of Urology, College of Physicians and Surgeons, Herbert Irving Pavilion, 11th Floor, 161 Fort Washington Avenue, New York, NY 10032, USA
    Expert Opin Investig Drugs 15:1191-200. 2006
  4. ncbi Zyflamend, a unique herbal preparation with nonselective COX inhibitory activity, induces apoptosis of prostate cancer cells that lack COX-2 expression
    Debra L Bemis
    Department of Urology, Columbia University Medical Center, New York, NY 10032, USA
    Nutr Cancer 52:202-12. 2005
  5. ncbi Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells
    X Yang
    Department of Urology, Columbia University Medical Center, New York, NY 10032, USA
    Oncogene 25:3436-44. 2006
  6. ncbi The use of herbal and over-the-counter dietary supplements for the prevention of prostate cancer
    Debra L Bemis
    Department of Urology, Columbia University, 161 Fort Washington Avenue, New York, NY 10032, USA
    Curr Urol Rep 7:166-74. 2006
  7. ncbi The use of herbal and over-the-counter dietary supplements for the prevention of prostate cancer
    Debra L Bemis
    Department of Urology, Columbia University, Irving-11, 161 Fort Washington Avenue, New York, NY 10032, USA
    Curr Oncol Rep 8:228-36. 2006
  8. ncbi A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells
    Xuezhen Yang
    Department of Urology, First Hospital, Peking University, Beijing, China
    Cancer Res 65:5263-71. 2005
  9. ncbi A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo
    Debra L Bemis
    Department of Urology, College of Physicians and Surgeons, School of Public Health, Columbia University Medical Center, New York, New York 10032, USA
    Clin Cancer Res 10:5282-92. 2004
  10. ncbi Tumor cell hypoxia and the hypoxia-response signaling system as a target for prostate cancer therapy
    Aristotelis G Anastasiadis
    Department of Urology, Columbia University, The College of Physicians and Surgeons, New York, NY 10032, USA
    Curr Drug Targets 4:191-6. 2003

Collaborators

Detail Information

Publications10

  1. ncbi Dietary agents/supplements hit the clinic for prostate cancer chemoprevention
    Debra L Bemis
    Department of Urology, Columbia University Medical Center, New York, NY 10032, USA
    Discov Med 7:33-8. 2007
    ..This paper discusses several agents currently under scientific scrutiny for prostate cancer chemopreventative activities and the data available, thus far...
  2. ncbi Anti-prostate cancer activity of a beta-carboline alkaloid enriched extract from Rauwolfia vomitoria
    D L Bemis
    Department of Urology, College of Physicians and Surgeons, Columbia University Medical Center, Herbert Irving Pavilion, New York, NY 10032, USA
    Int J Oncol 29:1065-73. 2006
    ..5 or 7.5 mg/kg Rauwolfia, respectively (Kruskal-Wallis test, p<0.001). The Rauwolfia vomitoria extract significantly suppressed the growth and cell cycle progression of LNCaP cells, in vitro and in vivo...
  3. ncbi Clinical trials of natural products as chemopreventive agents for prostate cancer
    Debra L Bemis
    Columbia University Medical Center, Department of Urology, College of Physicians and Surgeons, Herbert Irving Pavilion, 11th Floor, 161 Fort Washington Avenue, New York, NY 10032, USA
    Expert Opin Investig Drugs 15:1191-200. 2006
    ..This review discusses the preclinical and clinical data available for these dietary agents and describes relevant clinical trials currently being conducted...
  4. ncbi Zyflamend, a unique herbal preparation with nonselective COX inhibitory activity, induces apoptosis of prostate cancer cells that lack COX-2 expression
    Debra L Bemis
    Department of Urology, Columbia University Medical Center, New York, NY 10032, USA
    Nutr Cancer 52:202-12. 2005
    ..However, our data suggests that the effects are likely due to COX-independent mechanisms potentially involving enhanced expression of p21 and reduced expression of AR, pStat3, and pPKC(alpha/beta)...
  5. ncbi Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells
    X Yang
    Department of Urology, Columbia University Medical Center, New York, NY 10032, USA
    Oncogene 25:3436-44. 2006
    ....
  6. ncbi The use of herbal and over-the-counter dietary supplements for the prevention of prostate cancer
    Debra L Bemis
    Department of Urology, Columbia University, 161 Fort Washington Avenue, New York, NY 10032, USA
    Curr Urol Rep 7:166-74. 2006
    ....
  7. ncbi The use of herbal and over-the-counter dietary supplements for the prevention of prostate cancer
    Debra L Bemis
    Department of Urology, Columbia University, Irving-11, 161 Fort Washington Avenue, New York, NY 10032, USA
    Curr Oncol Rep 8:228-36. 2006
    ....
  8. ncbi A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells
    Xuezhen Yang
    Department of Urology, First Hospital, Peking University, Beijing, China
    Cancer Res 65:5263-71. 2005
    ..These findings have significant implications for the process through which prostate cancers progress to hormone resistance in humans...
  9. ncbi A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo
    Debra L Bemis
    Department of Urology, College of Physicians and Surgeons, School of Public Health, Columbia University Medical Center, New York, New York 10032, USA
    Clin Cancer Res 10:5282-92. 2004
    ..CONCLUSIONS: GCP has potent growth-inhibitory effects against prostate cancer cell lines in vitro and in vivo. These data suggest GCP has potential as an effective chemopreventive agent against prostate cancer cell growth...
  10. ncbi Tumor cell hypoxia and the hypoxia-response signaling system as a target for prostate cancer therapy
    Aristotelis G Anastasiadis
    Department of Urology, Columbia University, The College of Physicians and Surgeons, New York, NY 10032, USA
    Curr Drug Targets 4:191-6. 2003
    ....